Apr 30 2008, 6:00 AM EST
News source: Business Wire
Illumina, Inc. (NASDAQ:ILMN) and Genpathway today announced the
formation of a partnership to provide researchers whole-genome
chromatin immunoprecipitation (ChIP) sequencing services. Samples are
first prepared using Genpathway's FactorPath ChIP assays, and then
sequenced by the Genome Analyzer through Illumina's Sequencing
Services. Final data analysis is completed by Genpathway using their
proprietary software analysis tools. Combined, the Illumina and
Genpathway services provide researchers with access to a complete
ChIP-sequencing solution for identifying and quantifying transcription
factor binding sites across the entire genome.
Specifically, the combined services include cell or tissue
processing, antibody selection and qualification, ChIP using
Genpathway's optimized procedures for greater sensitivity and
specificity, ChIP DNA amplification, quality-control steps throughout
the assay, Sequencing Services using Illumina's Genome Analyzer, and
complete data analysis by Genpathway. Additional information about
Illumina's Sequencing Services with Genpathway's ChIP assays and
data-analysis services can be accessed at
www.illumina.com/ChIPsequencingservices.
"We are delighted to team up with Illumina, a world leader in
sequencing, to offer the most powerful and comprehensive
ChIP-sequencing services available," said Mary Harper, Ph.D., Chief
Scientific Officer of Genpathway. "One of the top applications for
sequencing is ChIP, a notoriously time-consuming and difficult
procedure. Combining Genpathway's expertise in ChIP and data-analysis
services with Illumina's high-throughput next-generation sequencing
technology and services provides researchers a faster path to
discovery."
"Our goal is to deliver high-quality products and services to
researchers sequencing genomes of any type or size, whether in drug
discovery and development, agricultural research, or basic academic
research," said Christian Henry, Acting General Manager of Illumina's
Sequencing Business. "By combining our Sequencing Services with
Genpathway's optimized ChIP assay and analysis capabilities, we are
providing researchers a complete solution for better understanding the
roles transcription factor binding and gene regulation plays in
disease development."
Researchers interested in initiating a ChIP-sequencing project
should contact Genpathway technical support at 858.457.3250, or visit
the Genpathway website at www.genpathway.com.
About ChIP Sequencing
ChIP sequencing enables researchers to study the complex
interactions between proteins and nucleic acids, and to gain insight
into the control and regulation of genes. By cross-linking proteins to
DNA at a given moment in a cell's life, and then capturing and
sequencing the DNA, scientists can discover where specific proteins
are bound to specific sites in the genome. This information helps
build a picture of the complex network of interactions that govern the
operation of human genes.
About Genpathway
Genpathway, Inc. (www.genpathway.com) is a leading provider of
ChIP and DNA methylation assays and services that identify and analyze
gene regulation by transcription factors and epigenetic changes, gene
transcription, and their corresponding biological pathways. These
assays, provided as a service by Genpathway, are used by
pharmaceutical and biotechnology companies in discovery and testing of
novel pharmaceuticals, biomarkers, and diagnostic tests as well as by
academic, government, and nonprofit research institutes and
agricultural companies worldwide. Genpathway and FactorPath are
registered trademarks or trademarks of Genpathway, Inc.
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer,
and marketer of next-generation life-science
ADVERTISEMENT
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
NewsArticles BlogsADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More News
Listen
Save
Comment
View All